Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROOF study in malignant pleural effusion from mesothelioma or non-small cell lung cancer
2013-005621-24Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, carboplatin, doxorubicin, vinorelbine, pemetrexed and 2 more in pleural mesothelioma and non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Accuracy of the drug profiling method. Started Jun 2014; status: active.
02
Drugs
gemcitabinecarboplatindoxorubicinvinorelbinepemetrexed
03
Conditions
pleural mesotheliomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-005621-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005621-24.